SecBot SecBot
8-K ·Filed Nov 2, 2026

TVTX

Travere Therapeutics, Inc.
BULLISH
Impact 6/10
Horizonmonths Processed14d 10h ago SEC0001438533-26-000074
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The 120% FILSPARI growth and 1,932 PSFs confirm strong commercial execution in IgAN and early FSGS launch momentum. The $113.1M IPRD charge for civorebrutinib is a one-time non-cash item; watch for the IND submission by year-end and Phase 3 HARMONY data in 2H 2027 as the next catalysts. The CEO transition is orderly and pre-announced.

DirectionBullish
Confidencehigh
Horizonmonths

Drugs in focus

TVTX drug pipeline →

pegtibatinase

● Neutral Named in this 8-K
Impact
Phase
Phase 3
Time to market
If the Phase 3 HARMONY study succeeds, a regulatory filing could follow the topline data (expected 2H 2027), with potential FDA approval potentially 12-18 months later, suggesting a possible 2029-2030 launch at the earliest.
Next catalyst
None dated

What to watchThe next major catalyst is the Phase 3 HARMONY topline data readout in 2H 2027. Positive data would position pegtibatinase as the first disease-modifying therapy for classical HCU and likely drive significant upside. Negative data or further manufacturing delays would be substantially damaging, though FILSPARI revenues provide a partial buffer.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$49.41
T+0 close · Nov 2, 2026 · via day close
Latest settled
+5.22%
T+5 · $51.99 · next T+20 in 15d
Vs SPY
+5.81%
α at T+5
Latest observation
+2.71%
T+8 · FF3 residual α
  1. T+0 · Nov 3 $49.41entry
  2. T+1 · 13d ago +6.09%α +4.44% · $52.42
  3. T+5 · 7d ago +5.22%α +5.81% · $51.99
  4. T+9 · todayOpen
  5. T+20 · in 15d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Travere Therapeutics reported Q3 2026 FILSPARI net product sales of $200.2M, up 120% YoY, and total revenue of $224.6M, well above the $195.3M consensus. However, GAAP net loss was $52.3M ($0.55/share) versus net income of $25.7M a year ago, driven by a $113.1M IPRD charge for the civorebrutinib license and higher R&D and SG&A spending. The company ended the quarter with $471.8M in cash and securities.

Key Financial Metrics

EPS (Adj.)
−$0.31
GAAP: $-0.55
Revenue
$224.6M
est $195.3M · +15.0% · +36.2% YoY

Key Facts

  • FILSPARI net product sales of $200.2M in Q3 2026, up 120% year-over-year from $90.9M
  • Total revenue of $224.6M, up from $164.9M in Q3 2025
  • 1,932 new patient start forms (PSFs) received during Q3 2026
  • GAAP net loss of $52.3M ($0.55 per share) vs net income of $25.7M ($0.29 per share) in Q3 2025
  • Non-GAAP net loss of $29.6M ($0.31 per share) vs non-GAAP net income of $52.8M ($0.59 per share) in Q3 2025
  • Recognized $113.1M in-process R&D expense for civorebrutinib licensing deal with Everest Medicines
  • Cash, cash equivalents and marketable securities of $471.8M as of September 30, 2026
  • Convertible debt increased to $603.5M from $311.7M at year-end 2025
  • Phase 3 HARMONY Study of pegtibatinase enrollment progressing, topline data expected 2H 2027
  • CEO transition announced: Bradley Campbell to succeed Eric Dube effective December 1, 2026

Financial Impact

FILSPARI sales grew 120% YoY to $200.2M, total revenue beat consensus by ~$29M; GAAP net loss widened to $52.3M due to $113.1M IPRD charge

revenuenet incomecash positiondebt

Segment Breakdown

SegmentRevenueGrowth
FILSPARI$200.2M+120.2%
Tiopronin products$20.0M-10.1%

Risk Factors

  • GAAP net loss widened sharply due to $113.1M IPRD charge and higher operating expenses
  • Convertible debt nearly doubled to $603.5M, increasing leverage
  • Phase 3 HARMONY Study results not expected until 2H 2027, a binary event
  • CEO transition introduces execution risk, though orderly

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001438533-26-000074
Document: tvtx-20261102.htm0001438533-26-000074
Document: 0001438533-26-000074-index-headers.html0001438533-26-000074
Document: 0001438533-26-000074-index.html0001438533-26-000074
Document: 0001438533-26-000074.txt0001438533-26-000074
8-K Data (Synthetic)0001438533-26-000074

Track record

21 reports on TVTX

Performance horizon

7 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +56.24% at T+60 after the Jun 2, 2026 report. 9 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $50.30 Now $49.70 −1.19% settles Nov 23
  2. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $48.87 to $51.56 Now $49.70 +1.70% ▲ +5.50% +2.21% vs SPY
  3. Nov 3, 202613d ago Institutional Cluster Bullish 4/10 Entry $49.41 to $51.99 Now $49.70 +0.59% ▲ +5.22% +5.81% vs SPY
  4. Nov 2, 202614d ago 8-K Bullish 6/10 Viewing Entry $49.41 to $51.99 Now $49.70 +0.59% ▲ +5.22% +5.81% vs SPY
  5. Sep 17, 20268w ago Insider Cluster Bearish 4/10 Entry $62.76 to $59.44 Now $49.70 +20.81% ▲ +5.29% +6.56% vs SPY
  6. Jul 9, 202618w ago 8-K Neutral 2/10 Entry $56.59 to $55.28 Now $49.70 −12.18% ▼ −2.31% −1.75% vs SPY
  7. Jun 16, 202621w ago Insider Cluster Neutral 2/10 Entry $54.14 to $57.69 Now $49.70 −8.20% ▲ +6.56% +7.60% vs SPY
  8. Jun 16, 202621w ago 8-K Neutral 2/10 Entry $54.14 to $57.69 Now $49.70 −8.20% ▲ +6.56% +7.60% vs SPY
  9. Jun 12, 202622w ago 144 Neutral 2/10 Entry $52.04 to $55.15 Now $49.70 −4.50% ▲ +5.98% +5.30% vs SPY
  10. Jun 2, 202623w ago 8-K Bullish 6/10 Entry $42.96 to $48.57 Now $49.70 +15.69% ▲ +13.06% +16.02% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 50m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026